SAB Biotherapeutics, Inc. (SABS) Reports Material Event to SEC
SAB Biotherapeutics, Inc. (NASDAQ:SABS) filed a Form 8-K with the Securities and Exchange Commission on March 10, 2026, disclosing a material event. SAB Biotherapeutics, Inc.'s…
Read more
